Biovico sp. z o.o.

Manufacture of medical and dental instruments and supplies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2008-12-11
Share capital
1,066,500.00 PLN
Activity description

Biovico is a biotechnology and pharmaceutical company focused on researching and developing rigorously tested healthcare products. They specialize in advancements in biologics and pharmaceuticals aimed at enhancing patient health and well-being globally.

Registered address
ul. Hutnicza 15B, 81-061 Gdynia, Poland
Email
Phone
Social media

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 9 days early. All were audited by a statutory auditor.

  • 202509/07/2026
  • 202408/07/2025
  • 202315/07/2024
  • 202221/06/2023
  • 202130/06/2022
  • 202011/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Other manufacturing22 / 493
Top 4.5%
Sector · Manufacturing368 / 11,963
Top 3.1%
City · Gdynia75 / 3,591
Top 2.1%
Voivodeship · Pomorskie424 / 20,062
Top 2.1%
Country · Poland6,884 / 297,069
Top 2.3%

Results vs industry

Revenue
This companyUSD 32.72mMedianUSD 287.80kAverageUSD 4.92m
Net profit
This companyUSD 11.02mMedianUSD 10.65kAverageUSD 206.72k
Operating costs
This companyUSD 21.86mMedianUSD 269.05kAverageUSD 4.50m
Assets
This companyUSD 30.43mMedianUSD 221.07kAverageUSD 5.78m

Websites

  • Google AnalyticsGoogle Tag ManagerLiteSpeed

Public procurement

97 tenders recorded as contractor: 44 national ($1,870,890) and 53 EU ($7,421,387).

SubjectAmount
“Supply of implants and consumables for the needs of the Orthopaedic and Trauma Surgery Clinic at Wojewódzki Szpital Zespolony w Kielcach”
$131.8K
Supply of disposable materials (drapes, sets, orthopaedic implants, membranes, accessories and instruments for urological and orthopaedic procedures) used in operating theatres, divided into 26 lots
$45,081
Supply of endoprostheses and other orthopaedic implants
$50,835

Trademarks

The company holds 18 active trademarks registered with the Polish Patent Office. 20 marks have expired or were not registered. The first mark was filed in 2009.

MarkNumberClassesStatusProtected until
CEBEDEFIX (word)Z.5162035Protected Jul 20, 2030
lipotris (word)Z.5140365, 10Protected May 27, 2030
Wilandt Pharma (word)Z.48947010Protected Aug 17, 2028
HALEVOX (word)Z.4894675, 10Protected Aug 17, 2028
TIRECO (word)Z.4864125Protected May 27, 2028
MarkProtected until
CEBEDEFIX (word)Jul 20, 2030
lipotris (word)May 27, 2030
Wilandt Pharma (word)Aug 17, 2028
HALEVOX (word)Aug 17, 2028
TIRECO (word)May 27, 2028

Job offers

The company has its own careers page: biovico.com/career.

Authorized Representatives

Aleksandra Taraszkiewicz-Maryjanowska age 40 – Management Board Member
Anna Barbara Łuba age 46 – Management Board Member
Norbert Wilandt age 39 – President of the Management Board

Manner of representation

In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
2,133$288,087.52100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2008-12-20.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$2M
Buildings and premises
$6.1M

MSiG notices

Publication dateEvent
Jan 14, 2026Commercial Companies Code notice

Public aid

40 public aid cases recorded, with a total value of $7,803,881.

PurposeGross amount
Aid for research and development projects: experimental development
–
Aid for research and development projects: industrial research
–
Aid for participation in trade fairs for small and medium-sized enterprises
–

European Funds

11 projects recorded: 10 from FE lists ($8,140,785) and 1 Commission grant (FTS) ($119,208).

ProjectEU co-financing
Development and implementation of a hybrid matrix with high chondrogenic potential for use in a single-stage procedure to repair articular cartilage defects
$1.8M
Assessment of the safety and efficacy of an innovative product based on a synthetic polymer, used for joint viscosupplementation.
$262.5K
Development and implementation of an innovative product based on cross-linked hyaluronic acid with added value, used as an effective anti-adhesion barrier.
$1.1M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Celon Pharma S.A.
Wörwag Pharma Operations sp. z o.o.
Biogen Poland sp. z o.o.
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed S.A.
Zakłady Farmaceutyczne Colfarm S.A.
Silesian Pharma sp. z o.o.
Bio-Gen sp. z o.o.
Reig Jofre sp. z o.o.
Synthaverse S.A.
Biofaktor sp. z o.o.

Change history

DateEvent
2025-03-03Name change
2022-03-04PKD change
2020-08-03PKD change
2018-09-11Address change
2016-11-04PKD change

FAQ

Last updated: 2026-10-07